DiaMedica Therapeutics Inc. (DMAC)
Data as of , from SEC Form 4 filings.
See up to 3 months of DMAC. The 7-day demo opens the 1M and 3M ranges and puts DMAC on your watchlist.
Start 7-day demoLatest DMAC insider trades
About DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
- MINNEAPOLIS, MN
- 35
- 2007
- XNAS
DMAC Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 60,200 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
DMAC insider transactions (Form 4)
2516 Form 4 filings on record, the earliest from Jul 25, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dietrich John Pauls - Officer | Grant or award | Voting Common Shares, no par value per share | 60,200 footnote F1 | $0.00 | - | |
| ||||||
| Randall Michael Giuffre | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Richard Kuntz | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Daniel J. O'Connor | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
 Tanya Lewis | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| Charles Pauling Semba | Grant or award | Stock Option (right to buy) | 40,412 | $0.00 | - | |
| James T. Parsons | Grant or award | Stock Option (right to buy) | 51,189 | $0.00 | - | |
| Dietrich John Pauls - Officer | Grant or award | Stock Option (right to buy) | 380,000 | $0.00 | - | |
 Scott Kellen - Officer | Grant or award | Stock Option (right to buy) | 162,000 | $0.00 | - | |
 Julie Krop - Officer | Grant or award | Stock Option (right to buy) | 67,500 | $0.00 | - | |
| James T. Parsons | Option exercise | Common Stock | 12,000 | $2.20 footnote F1 | $26K | |
| James T. Parsons | Option exercise | Stock Option (right to buy) | 12,000 | $0.00 | - | |
| ||||||
| Julie Krop - Officer | Grant or award | Stock Option (right to buy) | 450,000 | $0.00 | - | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 293,601 | $5.91 | $1.73M | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 70,414 | $5.99 | $422K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 8,233 | $6.00 | $49K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 71,107 | $5.86 | $416K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 48,172 | $5.96 | $287K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 59,788 | $5.96 | $357K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 338,265 | $6.00 | $2.03M | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 59,648 | $6.00 | $358K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 50,772 | $6.00 | $305K | |
| Jan Stahlberg - 10% Owner | Open-market purchase | Common Shares | 1,542,857 | $3.50 | $5.40M | |
| Koch Thomas von - 10% Owner | Open-market purchase | Common Shares | 2,857,142 | $3.50 | $10.00M | |
| Richard Jacinto II - 10% Owner | Open-market purchase | Voting Common Shares, no par value per share | 400,000 | $3.50 | $1.40M | |
DMAC insider trading FAQ
What is the latest insider trade for DMAC?
DiaMedica Therapeutics Inc. (DMAC) had 1 insider filing in the last 90 days, with the most recent on 2026-08-12. The full record for DMAC runs to 16 Form 4 filings, the earliest from 2025-07-25. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DMAC stock?
No insider purchases of DMAC were filed in the last 90 days. 12 purchases are on record for this company.
How many insiders are selling DMAC stock?
No insider sales of DMAC were filed in the last 90 days.
Where can I see DMAC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DMAC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Dietrich John Pauls view on EDGAR
- - Randall Michael Giuffre view on EDGAR
- - Richard Kuntz view on EDGAR
- - Daniel J. O'Connor view on EDGAR
- - Tanya Lewis view on EDGAR
- - Charles Pauling Semba view on EDGAR
- - James T. Parsons view on EDGAR
- - Dietrich John Pauls view on EDGAR
- - Scott Kellen view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where DMAC's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DMAC with a 7-day demo
- DMAC on your watchlist
- Every DMAC Form 4 filing on record
- Up to 3 months of DMAC price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
